Released May 15, 2024, after the close
10-Q filed May 15, 2024, 45 days after period end · 0000950170-24-060400
Q1 2024 · 10-Q
Revenue$140.00K$140.00K −37.2% vs Q1 2023−37.2% vs Q4 2023
Net Income-$12.67M-$12.67M N/M vs Q1 2023N/M vs Q4 2023
EPS Diluted-$0.24-$0.24 N/M vs Q1 2023no prior Q4 2023 on file
Operating Income-$13,982,000N/M
Operating Cash Flow$5,938,000N/M
Margins · derived
Operating margin-9987.1%−3607.3 pt vs Q1 2023
Net margin-9049.3%−3085.2 pt vs Q1 2023
What the release said
The release
Same quarter
| Metric | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|
| Revenue | $140.00K | $223.00K | $247.00K | $7.30M |
| Net Income | -$12.67M | -$13.30M | -$32.80M | -$19.40M |
| EPS Diluted | -$0.24 | -$0.25 | -$1.01 | -$0.66 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spero Therapeutics, Inc. · CIK 1701108 · Engraved from SEC EDGAR